43 The TRM rate was 3% in the ASCT group, with a nonsignificant trend toward impaired attention and executive function 2 years after therapy for those given WBRT. 43 For nonmyeloablative chemotherapy, 2 trials are in process.
← all excerpts
Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.
1
—
—